A review of prognostic molecular biomarkers for glioblastoma and their clinical significance for diagnosis and treatment DOI Creative Commons
Андрій Нетлюх, Т. А. Малышева, A.V. Zanevych

и другие.

Ukrainian Interventional Neuroradiology and Surgery, Год журнала: 2024, Номер 49(3), С. 59 - 71

Опубликована: Окт. 17, 2024

Glioblastoma (GBM) is a WHO grade IV malignant brain tumor with poor prognosis, and it the most common primary in adults. The estimated overall survival rate for patients GBM less than 1.5 years, 5-year of about 5 %. Current treatment standards include maximal (Gross total) resection, which rarely achieved due to diffuse-invasive nature these tumors, radiotherapy concomitant chemotherapy, such as temozolomide. New technologies, including genetic research advanced statistical methods, enhance therapeutic approaches create new opportunities. Certain genes are crucial understanding tumorigenesis each subtype associated specific epigenetic changes. Our goal was conduct an up-to-date review molecular markers, namely isocitrate dehydrogenase 1 2 (IDH1/2), O-6-methylguanine-DNA methyltransferase (MGMT), p53 protein, epidermal growth factor receptor (EGFR), platelet-derived (PDGFR), 1p/19q codeletion, telomerase reverse transcriptase (TERT), circulating cells, microRNAs. Established biomarkers widely used clinical neuro-oncology practice play critical role improving diagnostics, determining predicting responses. roles MGMT IDH1/2 well-established. Many studies indicate better outcomes from surgical radiation treatments mutations genes. We also highlighted potential biomarkers, especially easily accessible blood require thorough future evaluation their prognostic and/or predictive utility settings. However, on other EGFR, PDGFR, alpha-thalassemia mental retardation X-linked syndrome protein (ATRX), TERT, loss heterozygosity chromosome 10, complexes, microRNAs, remains promising. Overall, identifying enables selection effective improves prognosis gliomas.

Язык: Английский

The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies DOI Open Access
Aleksandra Krawczyk,

Gabriela Elzbieta Sladowska,

Barbara Strzałka‐Mrozik

и другие.

Cancers, Год журнала: 2025, Номер 17(5), С. 719 - 719

Опубликована: Фев. 20, 2025

Tumors of the central nervous system (CNS), especially gliomas, pose a significant clinical challenge due to their aggressive nature and limited therapeutic options. Emerging research highlights critical role gut microbiota in regulating CNS health disease. The composition is essential for maintaining homeostasis, as it modulates immune responses, oxidative status, neuroinflammation. microbiota–gut–brain axis, bidirectional communication network, plays pivotal cancer disease treatment, exerting its influence through neural, endocrine, immunological, metabolic pathways. Recent studies suggest that influences solidification tumor microenvironment dysbiosis may promote glioma development by modulating systemic inflammation stress, which contributes tumorigenesis progression. This review interrogates impact on glioma, focusing pathways such NF-κB, MAPK, PI3K/Akt/mTOR, Kynurenine/AhR drive proliferation, evasion, therapy resistance. Furthermore, we explore emerging strategies, including probiotics microbiota-based interventions, show potential these enhancing immunotherapies checkpoint inhibitors. By multifaceted interactions between microbiota, tumors, this microbiota-targeted therapies manipulation complement enhance current treatments.

Язык: Английский

Процитировано

1
Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets DOI Creative Commons

Ashley Irin Cortes Ballen,

Maryam Amosu,

Surya Ravinder

и другие.

Cells, Год журнала: 2024, Номер 13(18), С. 1574 - 1574

Опубликована: Сен. 19, 2024

Glioblastoma (GBM) is an aggressive and highly malignant primary brain tumor characterized by rapid growth a poor prognosis for patients. Despite advancements in treatment, the median survival time GBM patients remains low. One of crucial challenges understanding treating GBMs involves its remarkable cellular heterogeneity adaptability. Central to proliferation cells their ability undergo metabolic reprogramming. Metabolic reprogramming process that allows cancer alter metabolism meet increased demands survive often oxygen- nutrient-deficient microenvironment. These changes include Warburg effect, alterations several key pathways including glutamine metabolism, fatty acid synthesis, tricarboxylic (TCA) cycle, uptake utilization glutamine, more. complexity adaptability deeper offers hope developing more effective therapeutic interventions against GBMs.

Язык: Английский

Процитировано

6
The role of acetylation and deacetylation in cancer metabolism DOI Creative Commons
Cuicui Wang, Xiaoxin Ma

Clinical and Translational Medicine, Год журнала: 2025, Номер 15(1)

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance DOI Creative Commons
Simona D’Aprile, Simona Denaro,

Anna Gervasi

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13

Опубликована: Фев. 26, 2025

Glioblastoma (GBM) is one of the deadliest tumors due to its high aggressiveness and resistance standard therapies, resulting in a dismal prognosis. This lethal tumor carries out metabolic reprogramming order modulate specific pathways, providing metabolites that promote GBM cells proliferation limit efficacy treatments. Indeed, remodels glucose metabolism undergoes Warburg effect, fuelling glycolysis even when oxygen available. Moreover, recent evidence revealed rewiring nucleotide, lipid iron metabolism, not only an increased growth, but also radio- chemo-resistance. Thus, while on hand advantage for GBM, other it may represent exploitable target hamper progression. Lately, number studies focused drugs targeting uncover their effects therapy resistance, demonstrating some these are effective, combination with conventional treatments, sensitizing radiotherapy chemotherapy. However, heterogeneity could lead plethora alterations among subtypes, hence treatment might be effective proneural mesenchymal ones, which more aggressive resistant approaches. review explores key mechanisms involvement highlighting how acts as double-edged sword taking into account pathways seem offer promising options GBM.

Язык: Английский

Процитировано

0
Improving HEK293-based AAV-production using GSMMs, and a multi-omics approach DOI Creative Commons
Leopold Zehetner, Diana Széliová, Barbara Kraus

и другие.

Metabolic Engineering, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
RBMS1 promotes the proliferation of glioma cells via regulation of the c-Myc–SSH1 axis DOI Creative Commons
Shen Gu, Weining Wu, Chao Wu

и другие.

Biochemical and Biophysical Research Communications, Год журнала: 2025, Номер unknown, С. 151586 - 151586

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer DOI Open Access
Dini Kurnia Ikliptikawati,

Kei Makiyama,

Masaharu Hazawa

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(13), С. 7465 - 7465

Опубликована: Июль 7, 2024

The p53 family remains a captivating focus of an extensive number current studies. Accumulating evidence indicates that abnormalities rank among the most prevalent in cancer. Given numerous existing studies, which mostly on mutations, expression profiles, and functional perturbations exhibited by members across diverse malignancies, this review will concentrate more less explored facets regarding activation stabilization nuclear pore complex (NPC) cancer, drawing several integrates broad spectrum signals is subject to regulatory mechanisms enact necessary cellular response. It widely acknowledged each stage regulation, from synthesis degradation, significantly influences its functionality executing specific tasks. Over recent decades, large body data has established closely linked with protein stabilization, involve intricate interactions various components. These often transcend canonical pathways. This new knowledge expanded regulation genes themselves epigenomics proteomics, whereby interaction partners increase complexity compared earlier paradigms. Specifically, studies have recently shown involvement NPC such interactions, underscoring further regulation. Furthermore, we also discuss therapeutic strategies based developments field combination targeted therapies.

Язык: Английский

Процитировано

1
ZIPK collaborates with STAT5A in p53-mediated ROS accumulation in hyperglycemia-induced vascular injury DOI Creative Commons

Qichao Wu,

Tingting Xie,

Chang Fu

и другие.

Acta Biochimica et Biophysica Sinica, Год журнала: 2024, Номер unknown

Опубликована: Июль 1, 2024

In this study we investigate the role of Zipper-interacting protein kinase (ZIPK) in high glucose-induced vascular injury, focusing on its interaction with STAT5A and effects p53 inducible nitric oxide synthase (NOS2) expression. Human umbilical vein endothelial cells (HUVECs) are cultured under normal (5 mM) (25 glucose conditions. Protein gene expression levels assessed by western blot analysis qPCR respectively, while ROS measured via flow cytometry. ZIPK is manipulated using overexpression plasmids, siRNAs, shRNAs. The inhibitor TC-DAPK6 evaluated a diabetic rat model. Our results show that significantly upregulates ZIPK, STAT5A, p53, NOS2 expressions HUVECs, thus increasing oxidative stress. Silencing STAT5A reduces reactive oxygen species (ROS) accumulation. essential for accumulation, silencing ZIPK reverses these effects. Overexpression combined attenuates alterations expression, thereby preventing cell damage. Coimmunoprecipitation reveals direct between nucleus high-glucose condition. In rats, treatment decreases expressions. findings suggest plays critical injury STAT5A-mediated pathways, proposing potential therapeutic target complications.

Язык: Английский

Процитировано

1
Apoptotic effect of thymoquinone on OVCAR3 cells via the P53 and CASP3 activation DOI Creative Commons
Özge Karaosmanoğlu, Zeynep Kamalak, İlhan Özdemır

и другие.

Acta Cirúrgica Brasileira, Год журнала: 2024, Номер 39

Опубликована: Янв. 1, 2024

The limitations in cancer treatment and the inadequacy of classical methods have made it necessary to discover therapeutics treatment. cytotoxicity thymoquinone, which has quite different properties terms biological activities, ovarian cells, changes expression levels apoptotic genes (p53/caspase-3 (casp-3)) were investigated.

Язык: Английский

Процитировано

0
A review of prognostic molecular biomarkers for glioblastoma and their clinical significance for diagnosis and treatment DOI Creative Commons
Андрій Нетлюх, Т. А. Малышева, A.V. Zanevych

и другие.

Ukrainian Interventional Neuroradiology and Surgery, Год журнала: 2024, Номер 49(3), С. 59 - 71

Опубликована: Окт. 17, 2024

Glioblastoma (GBM) is a WHO grade IV malignant brain tumor with poor prognosis, and it the most common primary in adults. The estimated overall survival rate for patients GBM less than 1.5 years, 5-year of about 5 %. Current treatment standards include maximal (Gross total) resection, which rarely achieved due to diffuse-invasive nature these tumors, radiotherapy concomitant chemotherapy, such as temozolomide. New technologies, including genetic research advanced statistical methods, enhance therapeutic approaches create new opportunities. Certain genes are crucial understanding tumorigenesis each subtype associated specific epigenetic changes. Our goal was conduct an up-to-date review molecular markers, namely isocitrate dehydrogenase 1 2 (IDH1/2), O-6-methylguanine-DNA methyltransferase (MGMT), p53 protein, epidermal growth factor receptor (EGFR), platelet-derived (PDGFR), 1p/19q codeletion, telomerase reverse transcriptase (TERT), circulating cells, microRNAs. Established biomarkers widely used clinical neuro-oncology practice play critical role improving diagnostics, determining predicting responses. roles MGMT IDH1/2 well-established. Many studies indicate better outcomes from surgical radiation treatments mutations genes. We also highlighted potential biomarkers, especially easily accessible blood require thorough future evaluation their prognostic and/or predictive utility settings. However, on other EGFR, PDGFR, alpha-thalassemia mental retardation X-linked syndrome protein (ATRX), TERT, loss heterozygosity chromosome 10, complexes, microRNAs, remains promising. Overall, identifying enables selection effective improves prognosis gliomas.

Язык: Английский

Процитировано

0